Pharmacovigilance – News and Features

Targeting antidepressant medications to cells in the gut could not only be an effective treatment of mood disorders like depression and anxiety but may also cause fewer adverse side effects.

Researchers have introduced a proof-of-concept for a new class of antivirals that could be used against RNA viruses including SARS, Ebola and dengue.

This article explores some of the challenges in developing cell lines for therapeutics, such as cell line stability, and how they are being addressed.

New materials that reduce noise interference could help manage the side effects of brain pacemakers.

Scientists have developed a way to deliver radiation just to cancerous cells; the therapy combines a drug to mark the cancer cells for destruction and a radioactive antibody to kill them.

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS mutations, researchers showed.

Weight loss drugs like semaglutide may shrink heart muscle as well as waistlines, according to a new study. It found that the popular drug decreased heart muscle mass in lean and obese mice.

A UT Southwestern trial found selinexor, an FDA-approved drug, effective in KRAS-mutated non-small cell lung cancer (NSCLC). Combined with chemotherapy, it achieved tumor control in 80% of cases.

A clinical trial combining chemotherapy with immunotherapy blinatumomab reduced relapse risk in B-ALL by 61%. The study marked a milestone in pediatric leukemia care, with survival rates rising to 97.5%.

UCSF researchers have engineered T cells to temper overactive immune responses by targeting inflammation and soothing immune activity. The technology successfully protected transplanted pancreatic islet cells in a type 1 diabetes model.